Pingyangmycin

Pingyangmycin (also known as bleomycin A5) is an antitumor glycopeptide antibiotic belonging to the bleomycin family, which is produced by Streptomyces verticillus var. pingyangensis n.sp., a variety of Streptomyces verticillus. It was discovered in 1969 at Pingyang County of Zhejiang Province in China, and was brought into clinical use in 1978.[1]

Pingyangmycin
Clinical data
Other namesBleomycin A5
Pregnancy
category
  • D
Routes of
administration
intravenous, intra-arterial, intramuscular, intratumoral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Metabolismamidase
Elimination half-life1.3 hours
Excretionrenal (25-50%)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard100.031.221
Chemical and physical data
FormulaC57H89N19O21S2
Molar mass1440.56126 g·mol−1
3D model (JSmol)

In China, pingyangmycin has largely superseded bleomycin A2 (commonly known as "bleomycin"), since it is more effective, costs less, is easier to get, can treat a larger variety of cancers (such as breast cancer and liver cancer) and causes less lung injury.[2][3] Though it also results in pulmonary fibrosis, unlike bleomycin, its most serious side effect is anaphylactic shock, which is rare, but may happen even in a low dose, and can be fatal.[4] In addition, it causes a higher incidence of fever than bleomycin; the occurrence of this complication in patients is between 20 and 50%.

References

  1. Lin FT, Li DD, Yang XP, Li Q, Xue YC, Zhen YS (1979). "[Antitumor activity and preclinical pharmacologic evaluation of pingyangmycin (author's transl)]". Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 1 (3): 161–6. PMID 95444.
  2. Zheng JW, Yang XJ, Wang YA, He Y, Ye WM, Zhang ZY (October 2009). "Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients". Oral Oncology. 45 (10): 872–6. doi:10.1016/j.oraloncology.2009.02.011. PMID 19628423.
  3. Xu HZ, Zhang HY (October 1980). "[The isolation and identification of pingyangmycin (author's transl)]". Yao Xue Xue Bao = Acta Pharmaceutica Sinica. 15 (10): 609–14. PMID 6167140.
  4. Shou BQ, Mao Z, Zhang SL, Yang Z (October 2009). "[Allergy caused by minidose and low concentration Pingyangmycin: a case report]". Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West China Journal of Stomatology. 27 (5): 572–3. PMID 19927737.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.